Industry intelligence for founders building medical devices, surgical robotics, diagnostics, defense, and other regulated hardware. What I’m reading, what it means, and what it changes for the companies I work with.
June 17, 2026
How a 2018 De Novo Let Dexcom Put a Glucose Monitor on a Toddler
The FDA cleared Dexcom’s Stelo glucose monitor over the counter for children as young as two who do not use insulin, the first CGM sold without a prescription to anyone under eighteen. The hardware did not change; what changed is a label expansion riding on the integrated-CGM category Dexcom authored through a 2018 De Novo. For hardware founders, the lesson is that a De Novo is category authorship, not a punishment, and every later expansion becomes a cheaper filing against the standard you wrote.
Read more →June 16, 2026
Why OraSure Built a Collection Kit, Not a Better STI Test
OraSure won FDA clearance on June 11 for its Colli-Pee Dx kit, which lets a person collect a urine sample at home and mail it in to screen for four sexually transmitted infections on Roche’s installed cobas analyzers, per the company. The notable part is that OraSure built a collection device, not a new assay, because the thing that decides whether anyone benefits is whether a person ever produces a sample. For diagnostics and hard-tech founders, the lesson is to aim scarce product and regulatory effort at the dull step that gates adoption, not the impressive one that demos well.
Read more →June 15, 2026
GT Medical Raised $100M on Evidence, Not the Clearance It Already Had
GT Medical closed an oversubscribed $100 million Series E on June 9, led by Viking Global, per the company and MedTech Dive. The notable part is the timing: its GammaTile brain-tumor implant has been FDA cleared and selling since 2018, but the money only arrived after a randomized trial showed it cut twelve-month surgical bed recurrence to 1.3 percent against 15.4 percent for the standard of care. The lesson for hardware founders is that a clearance only lets you sell, while the comparative evidence is what unlocks adoption and capital.
Read more →June 14, 2026
The Robot Is the Giveaway. The Instruments Are the Business.
Restore Robotics won FDA clearance to remanufacture two more of Intuitive Surgical’s da Vinci instruments, giving it four total clearances on the da Vinci aftermarket, per MedTech Dive. The headline looks like a small aftermarket story, but the instruments are the real business in surgical robotics, and Restore is testing how well that recurring revenue is defended. The lesson for any hardware-plus-consumable founder is to know whether your recurring margin rests on physics, on regulation, or on nothing but habit.
Read more →June 13, 2026
NEURA’s $1.4 Billion Humanoid Bet. I’d Bet Narrow.
NEURA Robotics announced up to $1.4 billion in Series C funding on June 10, aimed at cognitive humanoids and serial production toward millions of robots by 2030, in what lead investor Tether calls one of the largest physical-AI rounds on record. The consensus reads it as the future of physical AI. I read the form-factor bet the other way: the most demanding buyers, defense first, are pulling toward untethered, edge-AI, narrow machines, not general-purpose humanoids that demo well. And up to $1.4 billion is expensive money before it is a milestone.
Read more →June 12, 2026
Penumbra’s Thunderbolt Stroke Clearance Is a Platform Play
Penumbra won FDA clearance for THUNDERBOLT, the first computer-assisted vacuum thrombectomy device authorized for acute ischemic stroke, per the company’s June 11 announcement. The headline reads as a new device, but the operator story is platform discipline: Penumbra re-pointed the aspiration engine that already runs its vascular business at the hardest indication it serves, and shipped it inside the RED catheters it already leads on. For founders, the lesson is product architecture, defining a core engine early enough that the second indication becomes a packaging decision instead of a fresh ground-up build.
Read more →June 11, 2026
Battlefield Drone Tech Came Home. The Dual-Use Line Is the Lesson.
The Pentagon ran CACI’s SkyValor counter-drone system for two days on the Arizona border and then cleared it for use across the entire military, while the same task force handed Perennial Autonomy a $500 million contract for a drone interceptor proven in Ukraine, per DefenseScoop. The detail founders should sit with is how thin the line is between the war version of a platform and the civilian one: strip the threat label off SkyValor’s autonomous sensing and net capture and you have airport, prison, and critical-infrastructure security. What a rival cannot copy is the real, adversarial failure data the system earned in the field, and which of your two roads generates that data is a product decision, not an accident.
Read more → Browse all Field Notes